Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 15/20 | 0.59 |
| ▸ | FAP | Q12884 | 13/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.59 |
| ▸ | PREP | P48147 | 6/20 | 0.50 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386522 | 1.00 | DPP4 (0.59) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL13259718 | 1.00 | DPP4 (0.59) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL15028066 | 0.90 | DPP4 (0.51) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL18780158 | 0.87 | FAP (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL15386478 | 0.85 | DPP4 (0.61) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL12658522 | 0.85 | DPP4 (0.61) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL13285634 | 0.83 | DPP4 (0.56) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL13263362 | 0.82 | DPP4 (0.54) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL15386545 | 0.82 | DPP4 (0.54) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL15386487 | 0.82 | DPP4 (0.65) | DPP4DPP7FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885DPP7 19/4885FAP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.